1. Home
  2. Directory
  3. California
  4. Long Beach
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1164045167

DR. ADAM MORENO DO
Prescription History 1164045167
Psychiatry & Neurology - Neurology in Long Beach, CA

NPI Status: Active since May 26, 2020

Contact Information

3711 LONG BEACH BLVD STE 4057
LONG BEACH, CA
ZIP 90807
Phone: (562) 414-4452

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ADAM MORENO DO, an active Neurology specialist practicing in Long Beach, CA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 73 documented patient claims. Among these therapy options, the most frequently utilized medication is Levetiracetam, which accounts for 20 claims alone.

Medication Index

D
F
L
M
No matching medications currently found on file.

Divalproex Sodium

Generic Formulation: Divalproex SodiumSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 14
30-Day Fills 18.0
Days Supply 540
CA State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills56.1
Peer Average Days Supply1,480
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.6% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $801.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$57.27

State Avg Cost Per Claim

$45.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.

Therapeutic Applications

This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.

Donepezil Hcl

Generic Formulation: Donepezil HclSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 14
30-Day Fills 20.1
Days Supply 604
CA State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills99.2
Peer Average Days Supply2,878
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 74.5% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $148.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.59

State Avg Cost Per Claim

$17.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Donepezil is used to treat confusion (dementia) related to Alzheimer's disease. It does not cure Alzheimer's disease, but it may improve memory, awareness, and the ability to function. This medication is an enzyme blocker that works by restoring the balance of natural substances (neurotransmitters) in the brain.

Felbamate

Generic Formulation: FelbamateSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
CA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills18.2
Peer Average Days Supply499
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,835.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$736.27

State Avg Cost Per Claim

$460.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.

Therapeutic Applications

Felbamate is used to treat severe seizures. This medication should be used only when you cannot take other medications or when other medications have not been able to control your seizures. Felbamate is known as an anticonvulsant or anti-epileptic drug.

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 20
30-Day Fills 36.0
Days Supply 1,080
CA State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills71.3
Peer Average Days Supply2,003
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.6% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,183.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$59.18

State Avg Cost Per Claim

$46.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Memantine Hcl

Generic Formulation: Memantine HclSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 13
30-Day Fills 19.2
Days Supply 552
CA State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills83.0
Peer Average Days Supply2,367
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 74.5% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $49.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.83

State Avg Cost Per Claim

$56.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Memantine is used to treat moderate to severe confusion (dementia) related to Alzheimer's disease. It does not cure Alzheimer's disease, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by blocking the action of a certain natural substance in the brain (glutamate) that is believed to be linked to symptoms of Alzheimer's disease.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ADAM MORENO DO provides transparency into local medical care patterns within Long Beach, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.